[go: up one dir, main page]

DK1975183T3 - Tumorspecifikke genkendelsesmolekyler - Google Patents

Tumorspecifikke genkendelsesmolekyler

Info

Publication number
DK1975183T3
DK1975183T3 DK08158547.3T DK08158547T DK1975183T3 DK 1975183 T3 DK1975183 T3 DK 1975183T3 DK 08158547 T DK08158547 T DK 08158547T DK 1975183 T3 DK1975183 T3 DK 1975183T3
Authority
DK
Denmark
Prior art keywords
core
antigen
amino acids
sequences
given
Prior art date
Application number
DK08158547.3T
Other languages
English (en)
Inventor
Steffen Goletz
Antje Danielczyk
Renate Stahn
Uwe Karsten
Peter Ravn
Peter Astrup Christensen
Original Assignee
Glycotope Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glycotope Gmbh filed Critical Glycotope Gmbh
Application granted granted Critical
Publication of DK1975183T3 publication Critical patent/DK1975183T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626Diabody or triabody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Polyesters Or Polycarbonates (AREA)
DK08158547.3T 2002-11-29 2003-12-01 Tumorspecifikke genkendelsesmolekyler DK1975183T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10256900A DE10256900A1 (de) 2002-11-29 2002-11-29 Tumorspezifische Erkennungsmoleküle
EP03788853A EP1572747B1 (de) 2002-11-29 2003-12-01 Tumorspezifische erkennungsmoleküle

Publications (1)

Publication Number Publication Date
DK1975183T3 true DK1975183T3 (da) 2012-07-30

Family

ID=32336015

Family Applications (3)

Application Number Title Priority Date Filing Date
DK03788853T DK1572747T3 (da) 2002-11-29 2003-12-01 Tumorspecifikke genkendelsesmolekyler
DK10012760.4T DK2386576T3 (da) 2002-11-29 2003-12-01 Tumorspecifikke genkendelsesmolekyler
DK08158547.3T DK1975183T3 (da) 2002-11-29 2003-12-01 Tumorspecifikke genkendelsesmolekyler

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK03788853T DK1572747T3 (da) 2002-11-29 2003-12-01 Tumorspecifikke genkendelsesmolekyler
DK10012760.4T DK2386576T3 (da) 2002-11-29 2003-12-01 Tumorspecifikke genkendelsesmolekyler

Country Status (11)

Country Link
US (3) US8088357B2 (da)
EP (3) EP2386576B1 (da)
AT (2) ATE555132T1 (da)
AU (1) AU2003293270A1 (da)
CY (3) CY1108389T1 (da)
DE (2) DE10256900A1 (da)
DK (3) DK1572747T3 (da)
ES (3) ES2387072T3 (da)
PT (3) PT1975183E (da)
SI (3) SI2386576T1 (da)
WO (1) WO2004050707A2 (da)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
JP5376948B2 (ja) 2005-09-13 2013-12-25 ナショナル リサーチ カウンシル オブ カナダ 腫瘍細胞活性を調節する方法及び組成物
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Aβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
SG10201706600VA (en) 2005-11-30 2017-09-28 Abbvie Inc Monoclonal antibodies and uses thereof
JP5419131B2 (ja) * 2005-12-12 2014-02-19 エーシー イミューン ソシエテ アノニム 治療的特性を有するβ1〜42特異的モノクローナル抗体
TWI551607B (zh) 2006-07-14 2016-10-01 Ac免疫公司 人類化抗體
HRP20150307T1 (hr) 2006-09-10 2015-04-24 Glycotope Gmbh Upotreba ljudskih stanica podrijetlom iz ljudske leukemije za eksprimiranje protutijela
EP1920781B1 (en) 2006-11-10 2015-03-04 Glycotope GmbH Compositions comprising a core-1 positive microorganism and their use for the treatment or prophylaxis of tumors
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (en) 2007-02-27 2008-09-04 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
CA2701793C (en) 2007-10-05 2017-04-25 Genentech, Inc. Use of anti-amyloid beta antibody in ocular diseases
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
WO2011063523A1 (en) 2009-11-24 2011-06-03 Alethia Biotherapeutics Inc. Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
EP2558494B1 (en) 2010-04-15 2018-05-23 AbbVie Inc. Amyloid-beta binding proteins
CN103179981B (zh) 2010-07-30 2017-02-08 Ac免疫有限公司 安全和功能性的人源化抗β‑淀粉样蛋白抗体
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
BR112014004065A2 (pt) 2011-08-22 2017-03-14 Glycotope Gmbh micro-organismos carregando um antígeno de tumor
CA2862739A1 (en) 2012-02-22 2013-08-29 Alethia Biotherapeutics Inc. Co-use of a clusterin inhibitor with an egfr inhibitor to treat cancer
WO2014127200A1 (en) * 2013-02-15 2014-08-21 Immunomedics, Inc. Chimeric and humanized anti-histone antibodies
EP3157950A4 (en) * 2014-06-20 2018-01-10 Stephen D. Gillies Influenza vaccines and methods of use thereof
WO2015200260A1 (en) 2014-06-24 2015-12-30 Immunomedics, Inc. Anti-histone therapy for vascular necrosis in severe glomerulonephritis
US10351621B2 (en) 2014-06-24 2019-07-16 Immunomedics, Inc. Anti-histone therapy in acute kidney injury
AU2018241780A1 (en) 2017-03-29 2019-08-15 Glycotope Gmbh Humanized anti-CD40 antibodies
JP2021519589A (ja) * 2018-03-29 2021-08-12 アールイーエムディー バイオセラピューティクス,インコーポレイテッドREMD Biotherapeutics,Inc インターロイキン17a(il−17a)に結合する抗体を用いた自己免疫障害及び炎症障害の治療
JP7416433B2 (ja) * 2018-04-10 2024-01-17 ノースウェスタン ユニバーシティ 標的指向性親和性ドメインに基づく膜タンパク質を含む細胞外小胞
BR112020023373A2 (pt) 2018-05-18 2021-02-09 Daiichi Sankyo Company, Limited conjugado, composição, e, uso de um conjugado ou de uma composição
CN112996801A (zh) * 2018-11-26 2021-06-18 北卡罗来纳州大学 用于捕获宿主细胞蛋白的肽配体
CN110684740B (zh) * 2019-08-09 2020-12-08 无锡傲锐东源生物科技有限公司 一种抗人泛素羧基末端水解酶-1(uch-l1)的单克隆抗体及其应用
WO2021191865A1 (en) * 2020-03-26 2021-09-30 Dusa Pharmaceuticals, Inc. Management of dermal neurofibromatosis lesions

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5683674A (en) 1987-01-07 1997-11-04 Imperial Cancer Research Technology Ltd. Antibody against human mucin core protein and method of preparing and using same
JP3698370B2 (ja) 1992-04-13 2005-09-21 ダナ−ファーバー キャンサー インスティチュート インク 癌腫抗原用抗体
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
DE4329004A1 (de) * 1993-08-28 1995-03-09 Max Delbrueck Centrum Monoklonale Antikörper gegen das Thomsen-Friedenreich-Antigen, ihre Herstellung und ihre Verwendung zum Tumornachweis
US5739277A (en) * 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
US5902582A (en) * 1995-09-05 1999-05-11 Chiron Corporation Use of TFPI inhibitor for treatment of cancer
US7147850B2 (en) 1999-08-18 2006-12-12 Altarex Medical Corp. Therapeutic binding agents against MUC-1 antigen and methods for their use
JP2003519096A (ja) 1999-08-18 2003-06-17 アルタレックス コーポレーション Muc−1抗原に対する治療用抗体およびその使用方法
GB0029360D0 (en) 2000-12-01 2001-01-17 Univ Nottingham Humanised antibodies and uses thereof
DE10303664A1 (de) 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren

Also Published As

Publication number Publication date
DE10256900A1 (de) 2004-06-24
PT1975183E (pt) 2012-07-12
EP1975183B1 (de) 2012-04-25
ES2523761T3 (es) 2014-12-01
EP2386576A1 (de) 2011-11-16
ATE555132T1 (de) 2012-05-15
SI2386576T1 (sl) 2014-12-31
CY1108389T1 (el) 2014-02-12
ATE399797T1 (de) 2008-07-15
SI1975183T1 (sl) 2012-08-31
EP1572747A2 (de) 2005-09-14
WO2004050707A3 (de) 2004-09-23
EP1572747B1 (de) 2008-07-02
ES2387072T3 (es) 2012-09-12
DE50310081D1 (de) 2008-08-14
EP1975183A1 (de) 2008-10-01
CY1112940T1 (el) 2016-04-13
US20060251668A1 (en) 2006-11-09
US20120149877A1 (en) 2012-06-14
US8617846B2 (en) 2013-12-31
SI1572747T1 (sl) 2008-12-31
WO2004050707A2 (de) 2004-06-17
PT2386576E (pt) 2014-11-11
DK2386576T3 (da) 2014-11-10
EP2386576B1 (de) 2014-08-13
PT1572747E (pt) 2008-10-14
ES2312842T3 (es) 2009-03-01
US9345794B2 (en) 2016-05-24
US8088357B2 (en) 2012-01-03
AU2003293270A8 (en) 2004-06-23
AU2003293270A1 (en) 2004-06-23
US20140099259A1 (en) 2014-04-10
DK1572747T3 (da) 2008-11-10
CY1115859T1 (el) 2017-01-25

Similar Documents

Publication Publication Date Title
DK1975183T3 (da) Tumorspecifikke genkendelsesmolekyler
ATE421537T1 (de) Erkennungsmoleküle zur behandlung und detektion von tumoren
FR2555199A1 (fr) Procede de clivage d'adn bicatenaire en n'importe quel point donne
NO20013371L (no) Ekspresjon og eksport av anti-fedmeproteiner som Fc- fusjonsproteiner
NO20015587D0 (no) Ekspresjon og eksport av interferon-<alfa> proteiner som Fc- fusjonsproteiner
DE69834824D1 (de) Nukleinsäure, welche einen von lektin abstammenden faktor zur präservierung von progenitorzellen kodiert
AR047345A1 (es) Vacuna para mejorar el crecimiento de animales a base de epitopos neutralizantes
WO2004100636A3 (en) Method for modifying transcription and/or translation in an organism
SE8105516L (sv) Syntetisk dna och forfarande for framstellning derav
WO1997016549A3 (en) Molecular cloning and characterization of molecules related to relaxin and the insulin family of ligands
EP1264843A3 (en) 38554, 57301 and 58324, Human organic ion transporters and uses therefor
ATE419350T1 (de) Humanes trp-ähnliches kalziumkanalprotein-2 tlcc- 2
ATE290549T1 (de) Ing2, ein mit iaps assoziiertes zellzyklusprotein,sowie zusammensetzungen, verfahren und verwendungen
EP1609482A1 (en) Drug for treating hemophilia and method of treating hemophilia using the same
Mulligan et al. Designing new peptide and protein therapeutics using adiabatic quantum annealers
WO2002051992A3 (en) 21163, a novel human prolyl oligopeptidase and uses therefor
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
Hay Who needs “normal” peptides?
WO2001021199B1 (en) Highly efficient dendritic cell-targeted dna-vaccination
WO2003091448A3 (en) 696803, a human transporter family member and uses therefor
TH44562A (th) สารคู่ที่ใช้ในการรักษามะเร็งต่อมลูกหมาก
ES8400876A1 (es) "un metodo para preparar una vacuna para estimular la produccion de anticuerpos contra el virus de la glosopeda".